黃 于芳

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Ovarian Epithelial Carcinoma 85%
3. Neoplasms 45%
4. Platinum 34%
5. Collagen Type XI 26%
6. Aldehyde Dehydrogenase 1 25%
7. Drug Therapy 24%
8. Down-Regulation 23%
9. Insulin-Like Growth Factor Binding Protein 2 23%
10. TP protocol 23%
11. Uterine Cervical Neoplasms 20%
12. Survival 19%
13. Somatomedins 18%
14. AZD8835 18%
15. Peritoneum 18%
16. Doppler Ultrasonography 17%
17. 4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide 16%
18. Trientine 14%
19. Therapeutics 14%
20. B-insulin 13%
21. Surgical Mesh 13%
22. Solanum 13%
23. Sodium-Hydrogen Exchanger 1 12%
24. Tissue Inhibitor of Metalloproteinase-3 12%
25. Gelsolin 11%
26. Phosphoinositide-3 Kinase Inhibitors 11%
27. liposomal doxorubicin 11%
28. Messenger RNA 11%
29. Aggressive Fibromatosis 11%
30. Carcinoma 11%
31. Carcinosarcoma 11%
32. Term Birth 11%
33. Sodium-Hydrogen Exchangers 10%
34. Heterografts 10%
35. Severe Acute Respiratory Syndrome 10%
36. Fibroma 10%
37. Papillary Carcinoma 10%
38. Calcitriol Receptors 9%